imatinib mesylate has been researched along with Opportunistic Infections in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kovacsovics, T; Meylan, P; Senn, L; Tarr, PE | 1 |
| Anthony, N; Shanks, J; Terebelo, H | 1 |
| Akiyama, H; Kanda, Y; Kasai, M; Kato, S; Yamaguchi, H | 1 |
| Antoniadis, A; Kalala, F; Kokoviadou, K; Korantzis, I; Plastiras, D; Speletas, M; Vyzantiadis, TA | 1 |
1 review(s) available for imatinib mesylate and Opportunistic Infections
| Article | Year |
|---|---|
[Present status in hematopoietic stem cell transplantation (discussion)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Opportunistic Infections; Piperazines; Pyrimidines; Rituximab; Tissue and Organ Procurement; Tissue Donors; Transplantation Conditioning; Transplantation Immunology | 2005 |
3 other study(ies) available for imatinib mesylate and Opportunistic Infections
| Article | Year |
|---|---|
Peritoneal tuberculosis after imatinib therapy.
Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphopenia; Male; Opportunistic Infections; Peritonitis; Peritonitis, Tuberculous; Piperazines; Pyrimidines | 2009 |
Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Opportunistic Infections; Piperazines; Pyrimidines | 2010 |
Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment.
Topics: Aged; Benzamides; Candida; Candidiasis; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lung; Male; Opportunistic Infections; Piperazines; Pneumonia; Polymorphism, Genetic; Pyrimidines; Radiography; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2008 |